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Utrecht, the NetherlandsObjectives This study sought to elucidate the underlying mechanism through which drug-eluting
balloons (DEB) restore coronary blood ﬂow, by assessing the coronary vessel before, immediately after,
and at 6-month follow-up with angiography, optical coherence tomography (OCT), and fractional ﬂow
reserve (FFR).
Background In-stent restenosis (ISR) treatment remains challenging. Drug-eluting balloons have been
shown to be a valid treatment option in several studies. These studies focused on efﬁciency of the
device, whereas the mechanisms of action of DEB in ISR treatment have not been investigated.
Methods In this prospective, single-center observational study, patients with ISR were treated with
a second-generation DEB. Serial angiographic, OCT, and FFR measurements were performed before
and after the procedure, as well as at 6-month follow-up.
Results Twenty-ﬁve patients were assigned to DEB treatment, with an angiographic and device
success of 100% and 92%, respectively. Late luminal loss was 0.01  0.43 mm. Median percent changes
[interquartile range] between pre-and post-procedure, and post-procedure and follow-up were,
respectively: lumen volume 75.1% increase [43.7 to 115.0], and 8% increase [14.0 to 25.8]; stent
volume 23.7% increase [15.5 to 40.0], and 1.2% decrease [6.9 to 5.9]; and neointimal
volume 14.4% decrease [29.2 to 9.5], and 15.8% decrease [38.1 to 28.3]. The FFR gradient
along the treated stent (difference in FFR between the distal and the proximal stent edge) was
0.37  0.18 pre-procedure, 0.06  0.04 post-procedure, and 0.05  0.05 at follow-up. In all
post-procedural OCT images, intrastent dissections were seen, which were sealed at follow-up OCT.
Conclusions DEB restore coronary blood ﬂow by means of a short-term mechanical effect, causing
an increase in lumen and stent volumes and compression of neointimal hyperplasia (with intra-stent
dissections). Due to the local drug effect, patency persists and may even improve at follow-up,
with further increase in lumen volume, decrease in neointimal volume, and complete sealing of
neointimal dissections. (J Am Coll Cardiol Intv 2013;6:569–76) ª 2013 by the American College of
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570Long-term clinical outcomes of percutaneous coronary
interventions (PCI) with stent implantation have improved
during the last decades, but a subgroup of patients is still
confronted with in-stent restenosis (ISR) (1,2). Initially, ISR
was treated with conventional or cutting balloons, although
with a high percentage of recurrent restenosis (3,4). Later,
brachytherapy and drug-eluting stent (DES) strategies were
explored. Although brachytherapy reduced recurrent reste-
nosis as compared to conventional balloon, DES proved to beSee page 577even superior, and they are currently the standard of care for
this indication (5–7). Recently, drug-eluting balloons (DEB)
have been considered as an alternative treatment strategy
instead of DES (8). There is evidence that DEB achieve at
least similar angiographic and clinical outcomes as DES,
without the need for an additional layer of metal (9).Abbreviations
and Acronyms
DEB = drug-eluting balloon(s)
DES = drug-eluting stent(s)
ISR = in-stent restenosis
FFR = fractional ﬂow reserve
OCT = optical coherence
tomography
PCI = percutaneous coronary
intervention
QCA = quantitative coronary
angiography
TLR = target lesion
revascularizationAvoiding additional stent place-
ment gives the operator more
treatment ﬂexibility in case of
future reinterventions in the tar-
get lesion. Moreover, prolonged
dual-antiplatelet therapy may not
be necessary when using DEB
technology (8,10,11).
Although the angiographic
and clinical effectiveness of DEB
in ISR has been demonstrated,
its exact mechanism of action
has not been fully exploited. No
literature is available about the
functional and intravascular mor-
phological changes induced byDEB over time in ISR treatment. Even more, data on
morphological ISR changes, even with other treatment
strategies, are scarce (12–14).
In this light, the aim of our study was to get a better
insight into the treatment of ISR lesions with DEB,
focusing on their short-term and mid-term mechanisms. To
achieve this, serial angiographic, fractional ﬂow reserve
(FFR), and optical coherence tomography (OCT) mea-
surements have been performed before intervention, im-
mediately after intervention, and at 6-month follow-up in
a series of ISR lesions treated with DEB.Methods
This study is a prospective, observational, single-arm study,
aimed at assessing functional and intravascular morpholog-
ical changes induced by the DEB in ISR lesions. The study,
carried out according to the Declaration of Helsinki, was
approved by the ethics committee of the University MedicalCenter Utrecht, and all included patients provided signed
informed consent.
Patient selection. Patients with stable or unstable angina
pectoris or silent ischemia, who were scheduled to undergo
PCI because of ISR of a bare-metal stent or DES, were
considered eligible. Documented ischemia had to be present.
Exclusion criteria were left ventricular ejection fraction
30%, acute myocardial infarction, left main disease, ostial
ISR (impossible to assess with OCT), life expectancy
<1 year, known renal failure (creatinine > 200 mg/dl), or
recurrent ISR.
Interventional procedure, study device, and OCT, FFR, and
angiographic data acquisition and analysis. All patients
enrolled in the study were treated with acetylsalicylic acid
(80 to 100 mg per day) and clopidogrel (300- to 600-mg
loading dose before the procedure, if needed, and 75 mg
per day maintenance). Heparin was administered intrave-
nously in boluses (70 to 100 U/kg) to maintain an activated
clotting time 250 s during the procedure. Administration
of glycoprotein IIb/IIIa inhibitors was left to the physician’s
discretion.
After obtaining coronary angiograms, patients underwent
sequential pre-dilation with standard balloons and dilation
with the DEB. More speciﬁcally, the standard balloon
diameter was sized with a 0.9:1 balloon-to-previous-stent
ratio and shorter than the intended DEB, and inﬂated with
high pressure (12 to 18 atm); the DEB diameter was sized
with a 1.1:1 balloon-to-previous-stent ratio and inﬂated
with low pressure (8 to 12 atm) during 60 s inﬂation. Post-
dilation was left to the physician’s discretion. Special care
was taken to position each DEB in order to avoid potential
geographic miss (i.e., DEB should extend a minimum of
5 mm proximal and distal to the pre-dilation balloon) and
excessive DEB overlap (to avoid double dose) in case of
multiple DEB use for long lesions (15). Additional bailout
stenting was performed in case of stent-edge dissection or
residual stenosis after balloon or DEB angioplasty. Acetyl-
salicylic acid was continued indeﬁnitely after the procedure,
and clopidogrel was continued for 3 months.
Methodological details on the study device used and the
ofﬂine OCT, FFR, and quantitative coronary angiography
(QCA) analysis can be found in the Online Appendix in the
Additional Methods section.
Follow-up and endpoints. All patients were scheduled to
undergo clinical and angiographic follow-up at 6 months.
In case an event occurred, detailed review of the hospital
ﬁles was performed. The main endpoints of this study were
several OCT and FFR parameters. Secondary endpoints
included: angiographic, device, and procedural success;
angiographic measures; and clinical outcomes according to
the Academic Research Consortium criteria (16). Angio-
graphic success was deﬁned as achievement of ﬁnal residual
stenosis <30% (by visual estimate) and Thrombolysis
In Myocardial Infarction (TIMI) ﬂow grade 3, using any
Table 1. QCA, Functional Measurements, and Clinical Events
QCA
Pre-
Procedure
(n ¼ 25)
Post-
Procedure
(n ¼ 25)
6-Month
Follow-Up
(n ¼ 23)
Reference vessel diameter, mm 2.35  0.46 d d
Minimal luminal diameter, mm 0.58  0.38 1.83  0.47 1.83  0.62
Diameter stenosis, % 75.3  16.1 27.5  15.9 26.0  18.3
Lesion length, mm 26.4  12.6 d d
Acute gain, mm d 1.26  0.61 d
Residual binary restenosis d 2 (8) d
Late-luminal loss, mm
In-stent d d 0.01  0.43
In-segment d d 0.03  0.43
Binary restenosis d d 4 (16)
FFR (n ¼ 22) (n ¼ 25) (n ¼ 23)
Distal target vessel 0.54  0.15 0.87  0.08 0.86  0.11
Distal of the stent 0.58  0.17 0.92  0.05 0.92  0.07
Proximal of the stent 0.96  0.07 0.97  0.03 0.96  0.05
In-stent gradient 0.37  0.18 0.06  0.04 0.05  0.05
Clinical Events at
6-Month Follow-Up d d (n ¼ 25)
Cardiac death d d 0
Myocardial infarction d d 0
Target lesion revascularization d d 2
Stent thrombosis d d 0
Values are mean  SD or n (%).
FFR ¼ fractional ﬂow reserve; QCA ¼ quantitative coronary angiography.
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571percutaneous method. Device success was deﬁned as angio-
graphic success using the DEB device. Procedural success
was deﬁned as angiographic success without the occurrence
of in-hospital major adverse cardiac events. All outcomes
were adjudicated by a clinical events committee.
Statistical analysis. Continuous variables are presented as
mean  SD or median [25th to 75th interquartile range].
Categorical variables are presented as counts and per-
centages. Continuous variables were compared between
2 groups using the paired Student t test or Wilcoxon
signed rank test, as appropriate. Categorical variables were
compared using the chi-square or Fischer exact test, as
appropriate. A 2-tailed p value of 0.05 was considered
statistically signiﬁcant.
Results
Patient and procedural characteristics. Overall, 25 patients
were included and underwent PCI for stable or unstable
anginal complaints, according to the protocol, between
August 2009 and May 2011. Baseline clinical and proce-
dural characteristics are shown in Online Tables 1 and 2.
Angiographic and procedural successes were achieved in all
patients. Device success was achieved in 23 (92%) patients:
in 1 patient, an additional stent was placed due to a dissec-
tion at the proximal edge of the old stent, and in another
patient, an additional stent was implanted because of
a residual signiﬁcant stenosis before the proximal edge of the
old stent. Both resulted in a good angiographic result.
Angiographic follow-up and adverse events at 6 months. The
QCA and clinical data are presented in Table 1. Two patients
refused to undergo angiographic control due to lack of
symptoms. In-stent and in-segment late luminal loss were
0.01  0.43 mm and 0.03  0.43 mm, respectively. At
follow-up, 4 patients (16%) had angiographic binary reste-
nosis, of which 2 (8%) had target lesion revascularization
(TLR). The 2 patients with a TLRwere a 65-year-old woman
and a 76-year-old man. The ﬁrst patient had a diffuse DES
restenosis as baseline lesion, which was treated successfully
with DEB. At 6-month follow-up, a diffuse recurrent reste-
nosis with a positive FFR was detected, and a clinically driven
TLR was performed with 2-limus DES. The second patient
was diabetic; his baseline lesion was a diffuse restenosis of a
bare-metal stent, treated successfully with DEB. At 6-month
follow-up, a recurrent diffuse restenosis with a positive FFR
was detected, and the lesion was treated with implantation
of a DES. Concerning the other 2 patients with binary
restenosis and without TLR, 1 had a 60% focal in-stent
diameter stenosis as measured by QCA, already present at
baseline (at the distal end of the previously implanted stent),
not treated with DEB and unchanged at follow-up. Both
after treatment and at follow-up, the FFR over this lesion
was negative. The other patient was diabetic and had a 53%
in-stent diameter stenosis as measured by QCA, withnegative FFR. Considering the patients had no complaints,
with a negative FFR, noTLRwas performed in either patient.
OCT and FFR. In 4 patients, pre-procedure OCT images
were not available due to an inability to cross the lesion with
the OCT catheter. In 2 patients, both pre-procedure and
post-procedure OCT data were not available, in 1 case
because of poor image quality, and in the other due to
technical issues with the OCT catheter (impossible acqui-
sition of images). In 3 patients, OCT data at follow-up were
not available. Two patients refused angiographic follow-up
(see the preceding text), and in 1 patient the OCT images
were of poor quality.
In 3 patients, pre-procedure FFR was not done due to
impossible passage of the lesion with the FFR wire. Post-
procedure FFR was performed in all patients. At follow-up,
only the 2 patients without angiographic follow up had no
FFR data. No complications occurred related to these
procedures. A comprehensive overview of the OCT and
FFR results are presented in Tables 1 to 3.
OCT-based lumen and stent volumes increased between
pre- and post-procedure, and lumen volume tended to
increase further at 6 months, meanwhile the stent volume
stabilized. Neointimal volume decreased between pre- and
post-procedure, and tended to further decrease at 6-month
follow-up (further data are also available in Online Table 3).
Table 2. OCT Analysis in Coupled Patients
Pre
(n ¼ 17)
Post
(n ¼ 17)
FU
(n ¼ 17)
p Value
Pre vs. Post Pre vs. FU Post vs. FU
Cross-section analyses
Stent length analyzed 23.0 [19.1–35.9] 22.9 [19.1–35.7] 22.8 [19.4–35.7] 0.22 0.60 0.12
Minimal mean lumen diameter, mm 1.13 [1.04–1.33] 1.97 [1.69–2.21] 2.02 [1.71–2.32] <0.001 <0.001 0.91
Minimal mean stent diameter, mm 2.49 [2.34–2.92] 2.75 [2.53–3.21] 2.92 [2.36–3.27] <0.001 0.04 0.57
Minimal lumen area, mm2 1.16 [0.93–1.72] 4.90 [2.71–5.57] 4.27 [3.02–6.28] <0.001 <0.001 0.74
Minimal stent area, mm2 5.42 [4.43–7.22] 8.00 [6.46–9.56] 7.95 [5.23–9.79] <0.001 <0.01 0.80
Maximum neointimal area, mm2 6.15 [5.01–7.75] 4.93 [3.94–5.35] 4.43 [3.61–3.72] <0.001 <0.01 0.91
Neointimal area stenosis, % 53.4 [43.7–59.3] 32.2 [29.5–35.9] 31.3 [22.0–39.2] <0.001 <0.01 0.65
Maximum neointimal area, % 83.4 [74.5–86.0] 48.3 [41.8–51.0] 42.4 [36.7–59.9] <0.001 <0.001 0.69
Lumen volume, mm3 78.5 [55.7–133] 152 [118–173] 178 [105–206] <0.001 <0.001 0.49
Stent volume, mm3 176 [132–237] 245 [180–261] 247 [176–273] <0.01 <0.01 0.80
Neointimal volume, mm3 87.5 [76.9–107] 76.2 [58.2–96.9] 57.3 [44.8–91.8] <0.001 <0.01 0.23
Malapposition volume, mm3 0 [0–0.36] 0.23 [0.06–0.58] 0.53 [0.11–1.54] 0.02 <0.01 0.19
Lumen symmetry* 0.75 [0.73–0.80] 0.69 [0.61–0.73] 0.73 [0.67–0.77] <0.01 0.09 0.01
Stent symmetry 0.89 [0.85–0.91] 0.84 [0.81–0.87] 0.87 [0.82–0.89] <0.01 0.03 0.52
Strut analyses
Total no. struts analyzed 7,522 5,510 6,696
Covered embedded struts, per lesion, % 100 [97.6–100] 97.2 [91.7–98.5] 97.3 [93.0–99.6] <0.01 <0.01 0.61
Covered protruding struts per lesion, % 0 [0–1.23] 0.48 [0–1.13] 0.66 [0–1.76] 0.86 0.10 0.07
Uncovered struts per lesion, % 0 [0–0.48] 1.85 [1.15–7.04] 1.32 [0.08–3.35] <0.01 <0.01 0.19
Malapposed struts per lesion, % 0 [0–0.21] 0 [0–0.17] 0 [0–1.72] 0.86 0.12 0.37
Covered struts overall (embedded and protruding)
per lesion, %
100 [99.4–100] 98.1 [91.9–98.9] 97.3 [95.4–99.9] <0.01 <0.01 0.43
Uncovered struts overall (uncovered and malapposed)
per lesion, %
0 [0–0.56] 1.85 [1.15–8.11] 2.70 [0.11–4.55] <0.01 <0.01 0.43
Values are median [interquartile range]. *Lumen symmetry lies between 0 and 1. A value of 1 means fully symmetric, with less symmetry with a decreasing value.
FU ¼ follow-up at 6 months; OCT ¼ optical coherence tomography; Post ¼ post-procedure; Pre ¼ pre-procedure.
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572Pre-procedure stent strut analysis showed minimal un-
covered or malapposed struts mainly located at the edges
of the stent, whereas there were few uncovered or malap-
posed stent struts visible directly after the procedure and
at follow-up, without differences in the time points of
acquisition.Table 3. Percentage Change in Coupled Patients
QCA
Pre-Post
(n ¼ 17)
Minimal lumen diameter change, % 213 [90.0 to 604]
Diameter stenosis change, % 66.2 [77.4 to 51.2]
OCT
Minimal lumen area change, % 278 [140 to 360]
Lumen volume change, % 75.1 [43.7 to 115]
Stent volume change, % 23.7 [15.5 to 40.0]
Neointimal volume change, % 14.4 [29.2 to 9.46]
FFR (n ¼ 20)
FFR stent gradient change, % 86.5 [92.6 to 64.0]
Values are median [interquartile range].
Abbreviations as in Tables 1 and 2.Functionally, the in-stent FFR gradient decreased after
the procedure, and tended to further decrease between post-
procedure and follow-up.
In all post-procedure OCT images, dissections were seen
through the DEB-dilated segment, mainly located where
the baseline lesion was most severe. These dissections werePre-FU
(n ¼ 17)
Post-FU
(n ¼ 17)
206 [124 to 509] 6.98 [5.55 to 16.8]
67.2 [81.5 to 48.9] 6.25 [51.9 to 46.8]
246 [99.7 to 391] 4.37 [22.6 to 26.5]
71.8 [44.6 to 117] 8.0 [14.0 to 25.8]
21.3 [10.2 to 41.3] 1.2 [6.87 to 5.89]
27.8 [49.1 to 2.69] 15.8 [38.1 to 28.3]
(n ¼ 20) (n ¼ 20)
87.3 [94.5 to 81.4] 28.3 [54.2 to 18.8]
Figure 1. Pre-PCI, Post-PCI, and Follow-Up Angiographic Images Coupled to Corresponding OCT Images: Focal ISR
Optical coherence tomography (OCT) images were captured in corresponding segments (i.e., same OCT segment is depicted between pre-PCI, post-PCI, and follow-up)
by means of a synchronization tool in the software. (A) Pre-PCI angiographic image shows a focal ISR, with the corresponding in-stent OCT image. (B) After the
procedure, coronary ﬂow is restored due to a mechanical effect. The OCT image demonstrates dissection of the neointimal plaque. (C) At follow-up, the coronary
lumen increases further due to the drug effect. Dissections as seen with OCT have been restored, with a smooth endothelial coverage of stent struts, with minimal
neointimal plaque. PCI ¼ percutaneous coronary intervention. See Online Video 1.
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573not visible on angiographic images and were left untreated,
because the angiographic result was satisfactory (Figs. 1,
2, and 3, Online Videos 1, 2, and 3). All these dissections
were completely healed at follow-up with restoration ofFigure 2. Angiographic Images Coupled to Corresponding OCT Images: Diffuse IS
(A) Pre-PCI angiographic image shows a diffuse in-stent restenosis (ISR), with the corr
due to a mechanical effect. The OCT image demonstrates a large stent-edge dissect
images. (C) At follow-up, the coronary lumen stabilizes due to the drug effect. Disse
Abbreviations as in Figure 1. See Online Video 2.a “near-circular” lumen surface inside the stent. Lumen
symmetry was used as surrogate measure for these dissec-
tions, in order to quantify them. Lumen symmetry was
signiﬁcantly lower directly after the procedure as comparedR With a Large Dissection
esponding in-stent OCT image. (B) After the procedure, coronary ﬂow is restored
ion of the neointimal plaque; remarkably, this is not seen on the angiographic
ctions as seen with OCT have been restored, with minimal neointimal plaque.
Figure 3. Angiographic Images Coupled to Corresponding OCT Images: Diffuse ISR With Microdissections
(A) Pre-PCI angiographic image shows a diffuse ISR, with the corresponding in-stent OCT image. (B) After the procedure, coronary ﬂow is restored due to a mechanical
effect. The OCT image demonstrates microdissections in the whole axial plane of the neointimal plaque. (C) At follow-up, the coronary lumen increases further
due to the drug effect. Dissections as seen with OCT have been restored, with a smooth endothelial coverage of stent struts, with minimal neointimal plaque.
Abbreviations as in Figure 1. See Online Video 3.
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574with pre-procedure and follow-up, whereas this was similar
between pre-procedure and follow-up (Table 2).
Discussion
This prospective observational study shows that a strategy
of balloon dilation and paclitaxel elution with DEB for
in-stent restenotic lesions restores and maintains coronary
blood ﬂow by means of a short-term mechanical effect
and a sustained pharmacological effect. Speciﬁcally, the
mechanical balloon dilation causes an increase in the
volume of the old stent, with concomitant compression and
dissection of the neointimal tissue. These phenomena lead
to an absolute increase in minimal lumen area to a value
that does not generate ischemia anymore. The pharmaco-
logical effect of paclitaxel maintains coronary patency at
follow-up, with a further trend toward a decrease in neo-
intimal hyperplasia volume, leading to a nonsigniﬁcant
increase in lumen volume. Despite this drug effect, no
signiﬁcant difference in uncovered or malapposed stent
struts is noted, with overall satisfactory stent strut coverage
at follow-up.
Interestingly, in the post-procedure OCT acquisitions,
the in-stent restenotic segment treated with DEB showed
extensive dissections of the neointimal tissue. These
dissections were not treated because the angiographic result
was satisfactory. All these dissections were completely healed
at follow-up, with restoration of a near circular lumen
surface inside the stent.Considering the neointimal decrease between pre-,
and post-procedure, this effect is attributable to a direct
mechanical effect of the pre-dilation balloon and the DEB
itself. This results in extra expansion of the restenotic stent
and in compression of the neointimal volume (achieved
also by means of several dissections as evident by OCT),
causing stent and lumen increase. Interestingly, the neo-
intimal volume tends to decrease beyond the intervention,
as assessed at follow-up, and this is most likely caused by
the drug effect. In experimental animal studies, it has been
demonstrated that paclitaxel causes apoptosis and necrosis
of endothelial and smooth muscle cells (17). Thus, it is
possible that our ﬁndings (regression of neointimal volume
with time) may be caused by similar cytotoxic mechanisms:
apoptosis and necrosis of neointimal tissue. However, it is
also possible that the healing process of the neointimal
dissections caused by the short-term balloon trauma can
lead with time to a cicatricial shrinkage of the neointimal
tissue, without additional recurrent proliferation because of
the cytostatic activity of paclitaxel (18). Although neo-
intimal volume decreases, there is still a high percentage of
strut coverage. This suggests a proper drug transfer deeper
in the neointimal tissue, toward the smooth muscle cells.
This may be due to the formula used on this DEB,
paclitaxel in combination with a hydrophilic excipient.
This excipient is added in order to increase the drug
transfer over the vessel wall surface to the smooth muscle
cells. Proper drug delivery to the smooth muscle cells is
imperative in order to reduce restenosis, but as this study
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575suggests, this is also important to prevent endothelial
toxicity. A previous study (19), by our group, assessed
the effects of another DEB without a similar hydrophilic
excipient. An important ﬁnding in that study is an
insufﬁcient reduction of neointimal hyperplasia, however,
with a higher percentage of uncovered and malapposed
struts than reported in the current study. Those ﬁndings
suggest a superﬁcial (toxic) effect of paclitaxel on the
endothelial cells, instead of inhibiting the deeper-laid
smooth muscle cell proliferation. In line with our current
ﬁndings, this suggests the importance of adequate delivery
of paclitaxel to the smooth muscle cells in order to reduce
the restenotic process and at the same time preventing
endothelial toxicity. A good endothelial coverage without
excessive neointimal proliferation might well underscore
a potential long-term beneﬁcial effect in reducing late
stent thrombosis without an increase in revascularization
rates.
Study limitations. First, selection bias may have occurred
in individual cases. Besides, patients with an ongoing
acute coronary syndrome were not considered eligible for
inclusion due to the complex nature of the study (i.e., pre-
and post-procedural FFR and OCT). Hence, only elective
patients were included in the study. Second, although
clinical and angiographic outcomes are promising, the
nature of this registry does not allow for comparison
with a reference technique. Yet, this registry strengthens
ﬁndings in other DEB studies. Finally, the number of
patients included is relatively low. However, in this study,
very sensitive techniques have been used that allow for
accurate assessment of the short-term and mid-term
mechanisms involved in restoring and maintaining coronary
blood ﬂow.
Conclusions
DEB restore coronary blood ﬂow by means of a short-
term mechanical effect, causing an increase in lumen and
stent volumes and compression of neointimal hyperplasia
(with intrastent dissections). Due to the local drug effect,
patency persists and may even improve at follow-up,
with a further increase in lumen volume, decrease in
neointimal volume, and complete sealing of neointimal
dissections. An early effective drug effect (in the thera-
peutic range for around 7 days) results in coronary
patency up to 6 months, which seems to be caused by an
appropriate distribution of paclitaxel into the vessel wall
due to the formula combining the drug with a hydrophilic
excipient.
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